Elisabetta Bianchi

IRBM Science Park, 600
Pomezia, 00071, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 28 publications

Discovery Process of Enlicitide, a Highly Engineered Macrocyclic Peptide Therapeutic, through Issue-Driven Fragment-Based Synthetic Assembly and SAR.

Discovery Process of Enlicitide, a Highly Engineered Macrocyclic Peptide Therapeutic, through Issue-Driven Fragment-Based Synthetic Assembly and SAR.

Journal: Journal of medicinal chemistry

Published: May 27, 2026

Post-translational modifications of huntingtin's N17 region: implications for self-association and membrane binding.

Post-translational modifications of huntingtin's N17 region: implications for self-association and membrane binding.

Journal: Biochimica et biophysica acta. Molecular basis of disease

Published: April 01, 2025

Optimization of Single Relaxin B-Chain Peptide Leads to the Identification of R2R01, a Potent, Long-Acting RXFP1 Agonist for Cardiovascular and Renal Diseases.

Optimization of Single Relaxin B-Chain Peptide Leads to the Identification of R2R01, a Potent, Long-Acting RXFP1 Agonist for Cardiovascular and Renal Diseases.

Journal: Journal of medicinal chemistry

Published: January 31, 2025

Camouflaging endovascular stents with an endothelial coat using CD31 domain 1 and 2 mimetic peptides.

Camouflaging endovascular stents with an endothelial coat using CD31 domain 1 and 2 mimetic peptides.

Journal: JVS-vascular science

Published: February 27, 2024

R2R01: A long-acting single-chain peptide agonist of RXFP1 for renal and cardiovascular diseases.

R2R01: A long-acting single-chain peptide agonist of RXFP1 for renal and cardiovascular diseases.

Journal: British journal of pharmacology

Published: November 09, 2023

Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor.

Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor.

Journal: Circulation

Published: May 01, 2023

Fatty acid acylated peptide therapeutics: discovery of omega-n oxidation of the lipid chain as a novel metabolic pathway in preclinical species.

Fatty acid acylated peptide therapeutics: discovery of omega-n oxidation of the lipid chain as a novel metabolic pathway in preclinical species.

Journal: Journal of pharmaceutical and biomedical analysis

Published: October 19, 2022

Characterization of a new potent and long-lasting single chain peptide agonist of RXFP1 in cells and in vivo translational models.

Characterization of a new potent and long-lasting single chain peptide agonist of RXFP1 in cells and in vivo translational models.

Journal: Scientific reports

Published: July 12, 2022

Discovery of Insulin/GLP-1/Glucagon Triagonists for the Treatment of Diabetes and Obesity.

Discovery of Insulin/GLP-1/Glucagon Triagonists for the Treatment of Diabetes and Obesity.

Journal: ACS medicinal chemistry letters

Published: May 09, 2022

Discovery of MK-1462: GLP-1 and Glucagon Receptor Dual Agonist for the Treatment of Obesity and Diabetes.

Discovery of MK-1462: GLP-1 and Glucagon Receptor Dual Agonist for the Treatment of Obesity and Diabetes.

Journal: ACS medicinal chemistry letters

Published: May 09, 2022

Development of ProTx-II Analogues as Highly Selective Peptide Blockers of Nav1.7 for the Treatment of Pain.

Development of ProTx-II Analogues as Highly Selective Peptide Blockers of Nav1.7 for the Treatment of Pain.

Journal: Journal of medicinal chemistry

Published: December 21, 2021

Guiding Chemically Synthesized Peptide Drug Lead Optimization by Derisking Mast Cell Degranulation-Related Toxicities of a NaV1.7 Peptide Inhibitor.

Guiding Chemically Synthesized Peptide Drug Lead Optimization by Derisking Mast Cell Degranulation-Related Toxicities of a NaV1.7 Peptide Inhibitor.

Journal: Toxicological sciences : an official journal of the Society of Toxicology

Published: December 13, 2021

Showing 1-12 of 28

Last Updated: 09/26/2026